Sunday, December 10, 2017 9:54:27 PM
1) Dr. Wolchok did discuss more extensively the CAR-T therapy he discussed only briefly during his Wistar presentation a year earlier. He noted the FDA had approved CAR-T therapies for use in humans, specifically that of KITE. He pointed to the recent acquisition of KITE by GILD, and also the acquisition of the private company discussed in post #s 3202239 and others[e.g.,'264, '256, '273],all in an attempt to improve the safety of such therapies that have been found unpredictably toxic--sometimes fatal as in trials by KITE and JUNO--by reason of cytokine storms. He cautioned that the administration of such therapy to patients must now be accompanied by readiness to quickly administer a mitigating steroid to control those toxicities.
2) The hour passed all too quickly---near 5:20, Dr. Wolchok drew attention to one or more papers by Zappadosi et al that discuss a molecule I had not seen mention before---alpha-GITR, pronounced "gitter" apparently.
3) A short Q&A session followed. It ended with an invitation for those who had further questions to step to the front to ask them before the reception began. For my part, I took the opportunity to remind Dr. Wolchok of the question I had asked him the year before at Wistar[CP's question]. He nodded he remembered that question. I then renewed that question to ask, in light of the year of further experience, data collection, posters presented at 2017 AACR[e.g. #1651] and 2017 SITC by PPHM and MSKCC, his discussion re CAR-T[my summary in paragraph 1) above], and clinical trials begun by other NCCN members[one by JHU, another by MGH and D-F], if anything had been done by MSKCC to initiate a clinical trial in human patients? He answered by stating that an experimental design had been completed for such a trial...for what indication(s) he did not say, nor did I ask.
Rather, I asked "when will that trial design be implemented"? He said "that depends on the company." as he left the auditorium.
In retrospect now, both of those 2 answers comprise multiple potentials, IMO.
More about that later.
Recent CDMO News
- Avid Bioservices to Participate at Upcoming Investor Conferences • GlobeNewswire Inc. • 05/07/2024 08:05:11 PM
- Avid Bioservices Reports Financial Results for Third Quarter Ended January 31, 2024 • GlobeNewswire Inc. • 04/24/2024 09:25:33 PM
- Avid Bioservices Announces Receipt of Deficiency Notice from Nasdaq Regarding Late Form 10-Q • GlobeNewswire Inc. • 03/20/2024 11:00:10 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/07/2024 11:30:11 AM
- Avid Bioservices Announces Pricing of Private Placement of Convertible Notes • GlobeNewswire Inc. • 03/07/2024 04:58:48 AM
- Avid Bioservices Announces Proposed Private Placement of Convertible Notes • GlobeNewswire Inc. • 03/06/2024 09:32:07 PM
- Avid Bioservices Announces Certain Preliminary Financial Results for Third Quarter Ended January 31, 2024 • GlobeNewswire Inc. • 03/06/2024 09:31:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2024 09:30:18 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 01/26/2024 09:57:52 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/13/2024 12:34:35 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 12:39:18 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 12:38:30 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 12:37:38 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 12:36:27 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 12:35:47 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/11/2024 12:56:02 AM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 01/08/2024 09:32:36 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 12:56:18 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 12:55:07 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 12:53:58 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 12:51:57 AM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 12/19/2023 09:05:52 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/19/2023 12:34:08 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/19/2023 12:33:03 AM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM